First Cervical Cancer Screening Delayed Until Age 21 — Less Frequent Pap Tests Recommended. – Women should have their first cervical cancer screening at age 21 and can be rescreened less frequently than previously recommended, reported by US researchers at ACOG.
FDA-approved drugs fulvestrant and raloxifene eliminate, prevent cervical cancer in mice. – Researchers eliminated cervical cancer in mice with two FDA-approved drugs currently used to treat breast cancer and osteoporosis. The study is published in the Proceedings of the National Academy of Sciences.
The World Health Organization grants prequalification to Cervarix: GSK?s vaccine to help combat cervical cancer in developing nations. – The World Health Organization (WHO) has awarded prequalification to Cervarix, GlaxoSmithKline’s cervical cancer vaccine. GlaxoSmithKline pharmaceutical company applied for WHO prequalification of Cervarix 2 years ago.
UK Department of Health has ruled out lowering the age of cervical cancer screening from 25 to 20 after experts reported that screening women under 25 could do more harm than good. – UK’s Advisory Committee on Cervical Screening (ACCS) has agreed unanimously for no change in the screening age as evidence showed that earlier screening could do more harm than good causing too many false positives and increase the risk of premature births in some women.
One step closer to turning off cancer genes with gene silencing technology for cervical cancer patients and also with no hair loss. – Researchers at The University of Queensland have developed a way to deliver drugs which can specifically shut down cancer-causing genes in tumour cells while sparing normal healthy tissues.
Study: Benefit to women not enough to sway men to get HPV vaccine – Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the vaccine, according to a new Florida State University study.
GARDASIL? is First Cervical Cancer Vaccine to Receive WHO Pre-qualification — WHO Pre-qualification Will Help to Facilitate Expanded Global Access and Implementation of HPV Vaccination Programs. – GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck’s cervical cancer vaccine, has been awarded World Health Organization (WHO) pre-qualification. GARDASIL is the first cervical cancer vaccine to receive WHO pre-qualification.
Studies of GARDASIL, Merck’s Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus Conference – In a study of an extended follow up of 290 women na?ve to HPV type 16, the HPV 16 component of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] was efficacious against HPV 16 infection for an average of 8.5 years after administration.
QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata, India. – QIAGEN and the Chittaranjan National Cancer Institute (CNCI) announced a collaboration to establish the first large-scale cervical cancer screening program for women in Kolkata, India.
Human papillomavirus genotype distribution in New Mexico cervical cancers – DNA from human papilloma virus type 16 (HPV16) and HPV type 18 (HPV18) were found in the majority of invasive cervical cancers in New Mexico in the 1980s and 1990s, according to a population-based study published in the March 24 online issue of the Journal of the National Cancer Institute.